Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailored-dose varenicline for post-quit urges to smoke
2010-022335-11Phase 3Completed
- Sponsor
- Barts and The London School of Medicine and Dentistry
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of varenicline in nicotine dependence (2 arms), sponsored by Barts and The London School of Medicine and Dentistry. Primary endpoint: Urges to smoke at 1 week after target quit date. Started Nov 2010; status: completed.
02
Drugs
varenicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2010-022335-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022335-11.